| __timestamp | Apellis Pharmaceuticals, Inc. | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 5496000 |
| Thursday, January 1, 2015 | 6356782 | 9786000 |
| Friday, January 1, 2016 | 4303743 | 6792000 |
| Sunday, January 1, 2017 | 10463151 | 7313000 |
| Monday, January 1, 2018 | 22639184 | 8382000 |
| Tuesday, January 1, 2019 | 67046483 | 10803000 |
| Wednesday, January 1, 2020 | 139401000 | 12944000 |
| Friday, January 1, 2021 | 176771000 | 21967000 |
| Saturday, January 1, 2022 | 277163000 | 32810000 |
| Sunday, January 1, 2023 | 500815000 | 46542000 |
Data in motion
In the competitive world of biotechnology, managing operational expenses is crucial for success. Apellis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Apellis has seen a dramatic increase in SG&A expenses, skyrocketing from approximately $2.9 million in 2014 to over $500 million in 2023. This represents a staggering growth of over 17,000%. In contrast, Xenon Pharmaceuticals has maintained a more conservative trajectory, with expenses growing from around $5.5 million in 2014 to nearly $46.5 million in 2023, marking an increase of about 745%. This divergence highlights differing strategic priorities and operational efficiencies. As investors and industry watchers analyze these trends, the question remains: which approach will yield greater long-term success?
Novo Nordisk A/S vs Xenon Pharmaceuticals Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novartis AG vs Apellis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Xenon Pharmaceuticals Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Xenon Pharmaceuticals Inc.
Incyte Corporation or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Apellis Pharmaceuticals, Inc.
Bio-Techne Corporation or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs ImmunityBio, Inc.
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs Geron Corporation